The next generation of the nation's only anthrax vaccine will be made in Lansing, an executive for Emergent BioSolutions Inc. said Tuesday.
There won't be any new jobs as a direct result of the $29 million federal contract Emergent received earlier this month for production of the new drug, Adam Havey, president of the company's biodefense division, said. But the new version of the vaccine will help keep current employees working.